Insmed Incorporated (NASDAQ:INSM) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in shares of Insmed Incorporated (NASDAQ:INSM) by 31.0% during the fourth quarter, HoldingsChannel reports. The firm owned 3,813 shares of the biopharmaceutical company’s stock after selling 1,715 shares during the period. SG Americas Securities LLC’s holdings in Insmed were worth $118,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of INSM. Cetera Advisor Networks LLC lifted its stake in shares of Insmed by 15.1% during the first quarter. Cetera Advisor Networks LLC now owns 11,405 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 1,500 shares in the last quarter. MetLife Investment Management LLC lifted its stake in shares of Insmed by 57.0% in the first quarter. MetLife Investment Management LLC now owns 62,884 shares of the biopharmaceutical company’s stock worth $1,478,000 after acquiring an additional 22,831 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in shares of Insmed in the first quarter worth about $660,000. Rhumbline Advisers lifted its stake in shares of Insmed by 4.7% in the first quarter. Rhumbline Advisers now owns 127,777 shares of the biopharmaceutical company’s stock worth $3,003,000 after acquiring an additional 5,723 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Insmed by 52.6% in the first quarter. Dimensional Fund Advisors LP now owns 624,309 shares of the biopharmaceutical company’s stock worth $14,670,000 after acquiring an additional 215,093 shares in the last quarter.

Insmed Price Performance

Shares of INSM stock opened at $24.80 on Friday. Insmed Incorporated has a 12-month low of $17.41 and a 12-month high of $32.00. The firm has a market capitalization of $3.68 billion, a price-to-earnings ratio of -4.64 and a beta of 0.92. The business has a 50 day simple moving average of $27.53 and a 200 day simple moving average of $27.03.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million during the quarter, compared to analyst estimates of $82.15 million. During the same period last year, the business earned ($1.20) earnings per share. Insmed’s quarterly revenue was up 41.1% on a year-over-year basis. On average, equities analysts anticipate that Insmed Incorporated will post -4.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently commented on INSM. Guggenheim boosted their price target on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. StockNews.com upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Barclays boosted their price target on Insmed from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. Wells Fargo & Company restated an “overweight” rating and set a $55.00 price objective on shares of Insmed in a research note on Monday, April 1st. Finally, UBS Group initiated coverage on Insmed in a research note on Tuesday, February 27th. They set a “buy” rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.64.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.